BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Asset Impairment Charges	$ 0.0		$ 0.0		$ 1.2	$ 0.0
Revenues	3,696.9		3,840.7		7,596.5	8,002.2
Contract with Customer, Liability	544.2				544.2		$ 558.5
Amortization of Deferred Sales Commissions	$ 8.7		$ 6.4		$ 15.9	$ 13.3
Percent of Revenue Contributed	100.00%		100.00%		100.00%	100.00%
Provision for income taxes	$ 117.5		$ 182.6		$ 265.5	$ 434.3
Net earnings	358.9		468.0		851.0	1,238.1
Net Income (Loss) Attributable to Parent	358.6	$ 491.6	467.4	$ 769.6	850.2	1,237.0
Stockholders' Equity Attributable to Parent	10,400.7	10,721.1	10,245.1	10,021.5	10,400.7	10,245.1	10,273.4	$ 9,359.7
Capitalized Contract Cost, Amortization	2.9		3.0		6.0	6.5
Deferred Revenue, Revenue Recognized					233.6	233.0
Revenue, Remaining Performance Obligation, Amount	6,132.6		5,616.6		6,132.6	5,616.6
Contract with Customer, Performance Obligation Satisfied in Previous Period	37.4		12.2		$ 69.1	28.7
Ownership percentage below which investments are generally accounted for on the cost method (in thousandths)					20.00%
LabCorp Diagnostics [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues	$ 2,255.4		$ 2,365.5		$ 4,709.5	$ 5,123.3
Percent of Revenue Contributed	61.00%		61.00%		62.00%	63.00%
Covance Drug Development [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues	$ 1,451.9		$ 1,495.2		$ 2,911.2	$ 2,933.4
Retained Earnings [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net Income (Loss) Attributable to Parent	358.6	491.6	467.4	769.6
Stockholders' Equity Attributable to Parent	$ 10,897.9	$ 10,948.4	$ 10,417.4	$ 10,171.9	$ 10,897.9	$ 10,417.4	$ 10,456.8	$ 9,402.3